Asensus Surgical Completes In Vivo Surgeon Lab for LUNA Surgical Robotic System
04 Januar 2024 - 10:15PM
Asensus Surgical, Inc. (NYSE American: ASXC), a medical device
company that is digitizing the interface between the surgeon and
the patient, announced a key development milestone for LUNA™, the
Company’s second-generation surgical robotic system.
During the week of December 11, 2023, the Company
hosted a Surgeon Lab in Research Triangle Park, North Carolina to
conduct an in vivo evaluation of LUNA’s hardware, software and
instruments in porcine models. The lab allowed nine participating
surgeons to evaluate the system's functionality through thirteen
different procedures across gynecology, urology, and general
surgery.
Anthony Fernando, President and CEO of Asensus
Surgical, provided a detailed update during a recent presentation,
highlighting surgeon feedback on the innovative features of LUNA.
For a closer look at the Surgeon Lab and insights from the
participating surgeons, a video is available on the Company’s
website at https://ir.asensus.com/events-and-presentations. The
video provides an overview of the system's features, demonstrating
its dextrous 5mm TrueWrist™ instruments range, its unique
surgeon console and its ergonomic benefits.
"The Surgeon Lab represents a crucial phase in the
LUNA development journey," noted Anthony Fernando, President and
CEO of Asensus Surgical. "The positive response from the
participating surgeons reaffirms our commitment to further
developing and delivering a surgical robotic system that not only
meets but exceeds expectations. The insights gathered will
contribute to the refinement of this late-stage engineering
prototype, moving us closer to a finalized product. We will provide
further details on LUNA's development and regulatory submission
timeline during our upcoming earnings call to be scheduled to
report on the fourth quarter and year end 2023.”
"The LUNA system showcased an impressive arm range
of motion and instrument dexterity, providing a level of precision
that is essential in surgical procedures. The strength and
reliability of the 5mm TrueWrist instrument line stood out,
offering versatility with different instrument types," mentioned
Dr. Amit Trivedi, Chair Department of Surgery, Pascack Valley
Medical Center in New Jersey. "The ergonomic design of the LUNA
surgeon console and the easy patient access are notable features. I
look forward to seeing how the system evolves and the potential
positive outcomes it may bring to surgery."
The LUNA Surgical System is Asensus’ next
generation digital surgery platform that is poised to revolutionize
the way surgery is performed.
LUNA, the Company’s Next Generation
Digital Surgery Platform
LUNA is designed to elevate the standards of
robotic-assisted surgery. The system integrates carefully crafted
hardware and software architecture to prioritize safety,
reliability, and performance. LUNA's features include a surgeon
console with unconstrained handles, an interactive touchscreen, and
an Ultra-HD 3D monitor. Additionally, the system boasts up to four
independent robotic manipulator arms for procedural flexibility,
alongside a unique instrument drive system supporting various
advanced instrumentation options. LUNA is currently under
development and has not been submitted to, or cleared by, the US
FDA or other global regulators, and is not available for sale in
any market.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface
between the surgeon and patient to pioneer a new era of
Performance-Guided Surgery™ by unlocking clinical intelligence for
surgeons to enable consistently superior outcomes and a new
standard of surgery. Based upon the foundations of Digital
Laparoscopy and the Senhance® Surgical System, the Company is
developing the LUNA Surgical System, a next generation robotic and
instrument system as a foundation of its Digital Surgery solution.
These systems will be powered by the Intelligent Surgical Unit™ to
increase surgeon control and reduce surgical variability. With the
addition of machine vision, Augmented Intelligence, and deep
learning capabilities throughout the surgical experience, we intend
to holistically address the current clinical, cognitive and
economic shortcomings that drive surgical outcomes and value-based
healthcare. The Senhance Surgical System is now available for sale
in the US, EU, Japan and select other countries. For a complete
list of indications for use, visit: www.senhance.com/indications.
To learn more about Performance-Guided Surgery, and digital
laparoscopy with the Senhance Surgical System visit
www.asensus.com.
Follow Asensus
Email Alerts:
https://ir.asensus.com/email-alerts
LinkedIn:
https://www.linkedin.com/company/asensus-surgical-inc/
Twitter: https://twitter.com/AsensusSurgical
YouTube:
https://www.youtube.com/@AsensusSurgical
Vimeo: https://vimeo.com/asxc
TikTok: https://www.tiktok.com/@asensus_surgical
Forward-Looking Statements
This press release includes statements relating to
the LUNA Surgical Robotic System development, including the
December 2023 surgeon lab and other statements regarding our future
plans and goals constitute "forward looking statements" within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, and are intended to
qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. Such statements
are subject to risks and uncertainties that are often difficult to
predict, are beyond our control and which may cause results to
differ materially from expectations and include whether the LUNA
Surgical Robotic System will be successfully developed and receive
regulatory clearances on the timeline we anticipate. For a
discussion of the risks and uncertainties associated with the
Company’s business, please review our filings with the Securities
and Exchange Commission (SEC), including our Annual Report on Form
10-K for the year ended December 31, 2022, filed with the SEC on
March 2, 2023 and our other filings we make with the SEC. You are
cautioned not to place undue reliance on these forward looking
statements, which are based on our expectations as of the date of
this press release and speak only as of the origination date of
this press release. We undertake no obligation to publicly update
or revise any forward-looking statement, whether as a result of new
information, future events or otherwise.
INVESTOR CONTACT:
Mark Klausner or Mike Vallie, 443-213-0499
invest@asensus.com
MEDIA CONTACT:
Dan Ventresca
Matter Communications
AsensusPR@matternow.com
617-874-5488
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/37115e8d-9772-4352-a919-c794b2d3aa77
Asensus Surgical (AMEX:ASXC)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Asensus Surgical (AMEX:ASXC)
Historical Stock Chart
Von Mai 2023 bis Mai 2024